Charles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug Discovery
Charles River Laboratories (NYSE: CRL) and Autobahn Labs have announced a collaborative program to accelerate academic drug discovery. The agreement establishes Charles River as the preferred research partner for Autobahn Labs, providing access to its drug discovery and development capabilities. Key points include:
1. Charles River has made an equity investment in Autobahn Labs.
2. Justin Bryans, Charles River's Chief Scientific Officer of Discovery, joins Autobahn's Board of Directors.
3. The partnership aims to advance novel academic science into transformational therapies across various modalities and disease areas.
4. Autobahn gains preferred access to Charles River's state-of-the-art drug discovery and development capabilities.
5. The collaboration is expected to expand partnerships with top-tier academic institutions and advance preclinical programs.
Charles River Laboratories (NYSE: CRL) e Autobahn Labs hanno annunciato un programma collaborativo per accelerare la scoperta di farmaci accademici. L'accordo stabilisce Charles River come il partner di ricerca preferito per Autobahn Labs, fornendo accesso alle sue capacità di scoperta e sviluppo di farmaci. I punti chiave includono:
1. Charles River ha effettuato un investimento azionario in Autobahn Labs.
2. Justin Bryans, Chief Scientific Officer di Discovery di Charles River, entra a far parte del Consiglio di Amministrazione di Autobahn.
3. La partnership mira ad avanzare la scienza accademica innovativa in terapie trasformative in vari ambiti e aree patologiche.
4. Autobahn ottiene accesso preferenziale alle all'avanguardia capacità di scoperta e sviluppo di farmaci di Charles River.
5. La collaborazione è prevista per espandere le partnership con istituzioni accademiche di alto livello e promuovere programmi preclinici.
Charles River Laboratories (NYSE: CRL) y Autobahn Labs han anunciado un programa colaborativo para acelerar el descubrimiento de medicamentos académicos. El acuerdo establece a Charles River como el socio de investigación preferido de Autobahn Labs, proporcionando acceso a sus capacidades de descubrimiento y desarrollo de medicamentos. Los puntos clave incluyen:
1. Charles River ha realizado una inversión de capital en Autobahn Labs.
2. Justin Bryans, Director Científico de Descubrimiento de Charles River, se une a la Junta Directiva de Autobahn.
3. La asociación busca avanzar en la ciencia académica novedosa hacia terapias transformadoras en diversas modalidades y áreas de enfermedad.
4. Autobahn obtiene acceso preferente a las capacidades de descubrimiento y desarrollo de medicamentos de vanguardia de Charles River.
5. Se espera que la colaboración amplíe las asociaciones con instituciones académicas de primer nivel y avance en programas preclínicos.
찰스 리버 연구소(뉴욕증권거래소: CRL)와 아우토반 랩스가 학문적 약물 발견을 가속화하기 위한 협력 프로그램을 발표했습니다. 이번 합의로 찰스 리버는 아우토반 랩스를 위한 선호 연구 파트너로 자리매김하게 되며, 약물 발견 및 개발 능력에 접근할 수 있습니다. 주요 사항은 다음과 같습니다:
1. 찰스 리버는 아우토반 랩스에 주식 투자를 했습니다.
2. 찰스 리버의 발견 부문 최고과학책임자인 저스틴 브라이언스가 아우토반의 이사회에 합류합니다.
3. 이 파트너십은 새로운 학문적 과학을 다양한 형태와 질병 영역의 혁신적인 치료법으로 발전시키는 것을 목표로 합니다.
4. 아우토반은 찰스 리버의 첨단 약물 발견 및 개발 능력에 대한 우선 접근 권한을 얻습니다.
5. 이번 협력이 선도적인 학술 기관과의 파트너십을 확장하고 전임상 프로그램을 발전시킬 것으로 예상됩니다.
Charles River Laboratories (NYSE: CRL) et Autobahn Labs ont annoncé un programme collaboratif pour accélérer la découverte de médicaments académiques. L'accord établit Charles River comme le partenaire de recherche préféré d'Autobahn Labs, offrant un accès à ses capacités de découverte et de développement de médicaments. Les points clés incluent :
1. Charles River a réalisé un investissement en actions dans Autobahn Labs.
2. Justin Bryans, Directeur Scientifique de la Découverte chez Charles River, rejoint le Conseil d'Administration d'Autobahn.
3. Le partenariat vise à faire progresser la science académique novatrice vers des thérapies transformationnelles dans divers domaines et modalités de maladies.
4. Autobahn bénéficie d'un accès privilégié aux capacités de découverte et de développement de médicaments à la pointe de la technologie de Charles River.
5. Cette collaboration devrait intensifier les partenariats avec des institutions académiques de premier plan et faire avancer les programmes précliniques.
Charles River Laboratories (NYSE: CRL) und Autobahn Labs haben ein Kooperationsprogramm zur Beschleunigung der akademischen Arzneimittelentdeckung angekündigt. Die Vereinbarung etabliert Charles River als den bevorzugten Forschungspartner von Autobahn Labs und ermöglicht den Zugang zu seinen Fähigkeiten in der Arzneimittelentdeckung und -entwicklung. Wichtige Punkte sind:
1. Charles River hat eine Eigenkapitalinvestition in Autobahn Labs getätigt.
2. Justin Bryans, Chief Scientific Officer von Discovery bei Charles River, tritt dem Vorstand von Autobahn bei.
3. Die Partnerschaft zielt darauf ab, innovative akademische Wissenschaft in transformative Therapien in verschiedenen Modalitäten und Krankheitsbereichen voranzutreiben.
4. Autobahn erhält bevorzugten Zugang zu den hochmodernen Fähigkeiten von Charles River in der Arzneimittelentdeckung und -entwicklung.
5. Die Zusammenarbeit wird voraussichtlich Partnerschaften mit führenden akademischen Institutionen erweitern und präklinische Programme voranbringen.
- Equity investment in Autobahn Labs, potentially leading to future returns
- Preferred partner status for Charles River, likely increasing service demand
- Expansion of partnerships with top-tier academic institutions, enhancing research pipeline
- Access to Autobahn's deal sourcing and venture creation expertise
- Potential for accelerated development of novel therapeutics across various disease areas
- None.
Charles River Laboratories' equity investment in Autobahn Labs is a strategic move that could significantly impact their financials positively in the long term. The partnership grants Charles River a foothold in cutting-edge academic biotech innovations. This could lead to the discovery of breakthrough therapeutics, which might translate into future revenue streams.
The collaboration also diversifies Charles River's investment portfolio, reducing risk by spreading it across various early-stage preclinical therapeutics programs. The financial commitment demonstrates confidence in Autobahn Labs' potential to deliver substantial returns. For investors, this indicates a calculated risk with promising upside potential.
The agreement between Charles River Laboratories and Autobahn Labs leverages advanced drug discovery and development technologies. As a preferred partner, Charles River will use its state-of-the-art capabilities to accelerate the translation of academic research into viable therapeutics.
This partnership is important in the tech-driven drug discovery landscape. It aligns with the industry trend of integrating academic research with commercial drug development, fostering innovation. For tech-savvy investors, this collaboration could signal future advancements in therapeutics and a competitive edge in the market.
The collaboration between Charles River and Autobahn Labs aligns with the increasing trend of academia-industry partnerships aimed at accelerating biotech innovation. This helps both entities de-risk their operations and expedite the drug development process, which is notoriously slow and expensive.
For the market, this partnership might signify a bullish trend in biotech collaborations, potentially leading to increased investor interest in Charles River and similar companies. The move reflects a strategic alignment to capture emerging opportunities in academic biotech, enhancing their market position.
- Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics
- Under the agreement, Charles River will make an equity investment in Autobahn Labs
- Justin Bryans, Chief Scientific Officer, Discovery at Charles River, named to Autobahn’s Board of Directors
Under the terms of the agreement, Charles River has made an investment in Autobahn Labs, joining a fundraising round led by Autobahn’s founding investor, Samsara BioCapital. Proceeds from the raise and partnership with Charles River will enable Autobahn to expand the number of partnerships with top-tier academic institutions, advance lead preclinical programs, and identify new opportunities for therapeutics development. In conjunction with the funding, Justin Bryans, Chief Scientific Officer, Discovery for Charles River, has joined Autobahn’s Board of Directors.
“I am looking forward to partnering with the Autobahn Labs team as they develop preclinical therapeutics programs,” said Justin Bryans, Chief Scientific Officer, Discovery, Charles River. “We expect our combined expertise will help progress drug discovery and development programs, ultimately delivering critical therapeutics to patients.”
“We are excited for Charles River to join Samsara BioCapital as an investor and partner in Autobahn’s mission to translate the best of academic biotech,” said Brendan O’Leary, CEO of Autobahn Labs. “Combining Charles River’s industry-leading drug discovery and development capabilities with Autobahn’s deal sourcing and venture creation expertise will allow us to efficiently de-risk academic research with significant therapeutic potential, from novel concept to preclinical drug candidate.”
About Autobahn Labs
Autobahn Labs is a new model for early-stage drug discovery and development, partnering with leading research institutions to accelerate the advancement of novel science to deliver transformational new therapies for patients. Founded in 2019 by Samsara BioCapital, we invest intellectual, financial and physical capital, applying our proven drug discovery framework to efficiently move projects from therapeutic hypothesis to novel drug candidates. For more information, visit www.autobahn-labs.com.
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724246400/en/
Charles River Investor Contact:
Todd Spencer
Corporate Vice President,
Investor Relations
781.222.6455
todd.spencer@crl.com
Charles River Media Contact:
Amy Cianciaruso
Corporate Vice President,
Chief Communications Officer
781.222.6168
amy.cianciaruso@crl.com
Source: Charles River Laboratories International, Inc.
FAQ
What is the purpose of the collaboration between Charles River Laboratories (CRL) and Autobahn Labs?
How has Charles River Laboratories (CRL) invested in Autobahn Labs?
Who from Charles River Laboratories (CRL) has joined Autobahn Labs' Board of Directors?
What benefits does Autobahn Labs gain from the partnership with Charles River Laboratories (CRL)?
